… used systemically, the antiviral immune response can prevent … treatment of colorectal cancer
liver metastasis [72, 73]. The ITu … has antitumor activity, and JX-594 may sensitize tumors to …

… after injection of JX-594 can enhance the anti-tumor … A phase II clinical trial showed that the
median total survival time of … balance between the anti-tumor immunity and antiviral immunity, …

… compared to the respective recombinant proteins. This may be … clinical studies explored
mRNA for anti-cancer vaccination, … In a randomized phase II clinical trial (NCT01446731), a DC …

… from a phase II trial that used a recombinant fusion protein … tolerability, and demonstrated
evidence of antitumor effect. A … are injected locally into the tumor to avoid pre-existing antiviral …

… in gastrointestinal tumors homologous recombination … in prostate cancer cell lines which
include protein transport along … sufficient to elicit anti-tumor immune responses. Of note, results …

… barriers, and antiviral host immunity during its delivery [10]. … has shown enhanced antitumor
activity [32]. Recent published data … phase II studies for patients with colorectal cancer, breast …

… proteins by malignant cells dysregulates the antitumor … on a phase I/II clinical trial with
metastatic solid malignancies … TTI-621 (SIRPαFc) is a fully recombinant fusion protein consisting of …

… toxicity profile and promising antitumor activity.53 The FDA … treatment for MSI-H or dMMR
metastatic colorectal cancer … antiviral therapy (viral load <100 IU/mL), but antiviral therapy was …

… of new anti-cancer drugs that kill or inactivate cancer cells … Cancer is a disease in which a
cell or group of cells exhibits … to prostate, lung, and colorectal cancers (CRC) in men and lung, …

… , the recombinant human p53 adenovirus anti-tumor injection (… cancer patients were enrolled
in phase II clinical trial, and … body's antiviral immune response to achieve effective therapy …